View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
17 April 2020

Corporate Announcement: Covid-19 Update

Our manufacturing plant Inke in Barcelona is fully operational, Neuraxpharm informs.

In light of the novel coronavirus (COVID-19) pandemic, as a pharmaceutical company present in 12 European countries, it is a Neuraxpharm priority and responsibility to protect the wellbeing and safety of our employees.

At the same time, we have a fundamental role in regard to the community and the healthcare industry to guarantee the supply of medicines addressed to patients.

We will continue serving our customers by working remotely where possible while ensuring the continuous manufacturing of our products highly prioritizing health and safety measures for our employees at our facilities.

Special recognition goes to all our professionals who continue working on-site for their exceptional commitment in order to continue serving our customers in the pharmaceutical industry in the best way possible.

We are proud of the strong dedication of our production teams to continue this vital work.

As an essential service during the coronavirus pandemic, all of us at Inke and Neuraxpharm are committed to safeguarding the supply of active pharmaceutical ingredients and medicines to our communities.

At Inke, we are taking the necessary precautions, and we are monitoring the situation closely as it develops.

For more information, please fill out the enquiry form attached to this page.

Inke provides high-added-value API ingredients for use in various respiratory therapies.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology